Monopar Therapeutics said it ended the second quarter of 2026 with $134.3 million in cash, cash equivalents and investments, up from the prior-year period and enough, the company said, to fund operations through at least Dec. 31, 2027.
The company’s net loss widened to $5.3 million, or $0.62 per share, in the quarter, from $2.5 million, or $0.35 per share, a year earlier.
Research and development spending rose sharply to $4.77 million from $1.73 million, an increase of $3.04 million. Monopar said the jump was driven mainly by a $2.03 million increase in contractor and consulting costs, a $721,228 increase in personnel expense including stock-based compensation, and a $288,752 increase in other R&D costs.
General and administrative expense increased to $1.88 million from $1.50 million, up $373,536. The company pointed to a $234,113 increase in personnel expense including stock-based compensation and a $198,988 increase in contractor and consulting costs, partly offset by a $59,565 decline in other G&A expense.
Interest income climbed to $1.30 million from $780,769, reflecting higher yields on U.S. Treasury securities and commercial paper, as well as larger bank balances following the company’s roughly $91.9 million capital raise in September 2025.
Other income was $32,158 in the quarter, compared with zero a year earlier.
On the development side, Monopar said it began rolling submission of the NDA for ALXN1840 on July 22, 2026. The FDA had already granted rare pediatric disease designation on June 30, 2026, giving the drug potential eligibility for a pediatric priority review voucher if approved.
The company also highlighted recent clinical presentations for ALXN1840, including new analyses from the phase 3 FOCUS trial showing greater neurologic improvement over time and better global clinical improvement versus standard of care in Wilson disease patients with neurologic symptoms. Monopar said phase 2 data presented at EASL showed the drug stabilized liver disease and improved neurologic symptoms and quality of life in heavily pre-treated patients.
Commercial preparations are also advancing. Monopar said Susan Rodriguez, who joined as chief commercial and strategy officer in March 2026, is leading launch planning, alongside recent additions to the board and commercial leadership team. The market has reacted to these announcements by moving the company's shares -2.4% to a price of $111.71. For the full picture, make sure to review Monopar Therapeutics's 8-K report.
